Navigation Links
Spherix Regains Compliance With NASDAQ Listing Rule
Date:5/24/2011

maceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Announces First Quarter Financial Results
2. Spherix Announces Reverse Stock Split Effective May 6, 2011
3. Spherix to Effect Reverse Stock Split
4. Spherix Announces 2010 Financial Results
5. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
6. Spherix to Present at the 13th Annual BIO CEO & Investor Conference
7. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
8. Spherix to Present at Two Upcoming Prominent Finance Conferences
9. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
10. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
11. Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... Arlington, Massachusetts (PRWEB) October 22, 2014 ... recently announced the release of a new infographic, ... was to create a beautifully designed, easy to follow ... Ebola's transmission, areas of outbreak, symptoms and prevention. , ... have discovered that the 2014 Ebola outbreak represents not ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Biotechnology,International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the ... plants and,animals in the People,s Republic of China, today ... 2008., Third Quarter 2008 Highlights -- ... the third quarter of 2007 ...
... revenue with reduction in loss for the quarter, ... (OTC Bulletin Board: EROX) ("HPS" or "the Company") today,announced ... September 30,2008. For the three month period ending September ... from the revenues of $239,000 in the,prior year period, ...
... Driven by the human genome project, and research in the ... antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents ... towards proteomics from genomics in the post-genome-project research period is ... years. , ...
Cached Biology Technology:Yongye Biotechnology Announces Record Third Quarter Results 2Yongye Biotechnology Announces Record Third Quarter Results 3Yongye Biotechnology Announces Record Third Quarter Results 4Yongye Biotechnology Announces Record Third Quarter Results 5Yongye Biotechnology Announces Record Third Quarter Results 6Yongye Biotechnology Announces Record Third Quarter Results 7Yongye Biotechnology Announces Record Third Quarter Results 8Yongye Biotechnology Announces Record Third Quarter Results 9Yongye Biotechnology Announces Record Third Quarter Results 10Yongye Biotechnology Announces Record Third Quarter Results 11Yongye Biotechnology Announces Record Third Quarter Results 12Human Pheromone Sciences Announces Third Quarter Results 2Human Pheromone Sciences Announces Third Quarter Results 3Human Pheromone Sciences Announces Third Quarter Results 4World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 2World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 3
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Diabetes Center have found genetic regions that, when defective, allow ... a series of mis-steps that lead to type 1 diabetes. ... Immunity, the researchers are now trying to hone in on ... , “The significance of this study is that we found ...
... found to defy the most basic tenet of sexual ... sex, according to Howard Hughes Medical Institute researchers at ... 2005, issue of Nature, the researchers reported that, in ... "sex" can mate and produce offspring. Infection with the ...
... identified the proteins that allow specific brain cells to "change ... the cell. The findings, described in the March 24 issue ... day using it to protect cells that die in Lou ... what comes into the living room, these brain cells are ...
Cached Biology News:Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3Same-Sex Mating Discovered in a Toxic Fungus 2Same-Sex Mating Discovered in a Toxic Fungus 3Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3